Skip to main content
. 2016 Dec 23;13(4):791–801. doi: 10.1080/21645515.2016.1248326

Figure 3.

Figure 3.

Antibody responses for (A) monovalent rAT; (B) bivalent rAT; (C) monovalent rLukS-PV; and (D) bivalent rLukS-PV formulations following first and second vaccination in the completer population. Visits are based on pre-defined windows for serology sample collection and not on the nominal visit. All out-of-window sample collections are excluded). After Day 84, the number of subjects who received the booster dose in the bivalent 50 µg cohorts was six.